Sean Smith, ImmunOs Therapeutics CEO
A former Merck director's Pfizer-backed biotech will take on his old bosses in nascent LILRB field
Only a handful of biotechs are going after LILRBs, components of the innate immune system. But after an initial crop of data out of Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
